SPY306.35+0.80 0.26%
DIA256.78+1.51 0.59%
IXIC9,552.44+0.39 0.00%

HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Raises Price Target to $52

HC Wainwright & Co. reiterates Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and raises the price target from $41 to $52.

Benzinga · 05/11/2020 11:37

HC Wainwright & Co. reiterates Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and raises the price target from $41 to $52.